Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Related Posts

GSK Pharma forays into gynaecological cancer treatment in India

GlaxoSmithKline Pharmaceuticals Ltd. stock zoomed as much as 2% on Monday, August 25. This movement in shares came after the company announced its entry into the oncology segment in India…

Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

Hyderabad:  Chief Minister A Revanth Reddy said Hyderabad was India’s emerging hub of biotech, pharma, and medical technology innovation, with the ambition to become a $1 trillion economy by 2034.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

GSK Pharma forays into gynaecological cancer treatment in India

GSK Pharma forays into gynaecological cancer treatment in India

Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

Hyderabad rising in biotech, pharma, medtech innovation: Revanth Reddy

DCGI issued alert regarding theft of Novo Nordisk injectables

DCGI issued alert regarding theft of Novo Nordisk injectables

Two firms fined for selling spurious cosmetic products

Two firms fined for selling spurious cosmetic products